Skip to search formSkip to main contentSkip to account menu

Ensituximab

Known as: Anti-CPAA Monoclonal Antibody NPC-1C, Anti-Colorectal and Pancreatic Carcinoma-Associated Antigen Monoclonal Antibody NPC-1C, NPC-1C 
A chimeric monoclonal antibody against human colorectal and pancreatic carcinoma-associated antigens (CPAAs) with potential immunomodulating and anti… 
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Ensituximab (E) in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results of a phase I/II clinical trial.
3081Background: E is an investigational, novel, chimeric monoclonal IgG1 antibody derived from an immunogenic neoantigen with… 
2016
2016
A phase II therapeutic, open label, multi-center clinical trial of NPC-1C, a chimeric monoclonal antibody(mAb), in adults with chemotherapy refractory metastatic colorectal cancer (mCRC), initial…
500 Background: NEO-102 is a novel chimeric mAb targeting a variant of MUC5AC with specificity to colorectal cancer. Its… 
2015
2015
A phase I/II multicenter study of the chimeric monoclonal antibody NEO102 (NPC-1C) in adults with refractory pancreatic (PC) and colorectal cancer (CC).
240 Background: NPC-1C (NEO102) is a novel chimeric monoclonal antibody that recognizes a variant form of MUC5AC expressed… 
2013
2013
A phase II study of NPC-1C: A novel therapeutic monoclonal antibody (mab) to treat pancreatic (P) and colorectal (CR) cancers.
3070 Background: NPC-1C is a chimeric mab developed to treat P and CR cancers. This mab was selected from a panel of hybridomas… 
2012
2012
A phase I safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers.
233 Background: NPC-1C (NEO-101; ensituximab) is a chimeric monoclonal antibody being developed as a novel biological treatment… 
2012
2012
A phase I/IIA safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers.
233 Background: NPC-1C (NEO-101; ensituximab) is a chimeric monoclonal antibody being developed as a novel biological treatment… 
2011
2011
Abstract 4584: Pre-clinical studies of a novel antibody to treat pancreatic and colorectal cancers
Introduction: NPC-1C is a chimeric monoclonal antibody being developed as a novel biological treatment for pancreatic and… 
2011
2011
Use of two novel antibodies that detect tumor-specific antigens for the detection of colorectal cancer.
e21082 Background: The early diagnosis of colorectal cancers remains an area of high unmet medical need, as underscored by the U… 
2011
2011
Development of a new stool biomarker ELISA for the early detection of colorectal cancer.
390 Background: An ELISA was developed using NPC-1C, a novel antibody that reacts with an antigen expressed specifically by human… 
1993
1993
Boletim agrometeorológico 1993: Campo Experimental de Maués: Embrapa-CPAA.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)